+Compare
RPHM
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
196.54M

RPHM Reneo Pharmaceuticals Forecast, Technical & Fundamental Analysis

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for RPHM with price predictions
07:00 PM EST Dec 03, 2023

RPHM's RSI Oscillator ascends from oversold territory

The RSI Indicator for RPHM moved out of oversold territory on November 17, 2023. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 17 similar instances when the indicator left oversold territory. In of the 17 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 37 cases where RPHM's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on December 01, 2023. You may want to consider a long position or call options on RPHM as a result. In of 48 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for RPHM just turned positive on December 01, 2023. Looking at past instances where RPHM's MACD turned positive, the stock continued to rise in of 24 cases over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where RPHM advanced for three days, in of 153 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

RPHM moved below its 50-day moving average on November 08, 2023 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for RPHM crossed bearishly below the 50-day moving average on November 10, 2023. This indicates that the trend has shifted lower and could be considered a sell signal. In of 6 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RPHM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

RPHM broke above its upper Bollinger Band on December 04, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for RPHM entered a downward trend on December 01, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.759) is normal, around the industry mean (20.645). P/E Ratio (0.000) is within average values for comparable stocks, (137.286). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (7.704). Dividend Yield (0.000) settles around the average of (0.035) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (329.397).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. RPHM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RPHM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sorrento Therapeutics (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.29B. The market cap for tickers in the group ranges from 402 to 464.61B. NVO holds the highest valuation in this group at 464.61B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 6%. For the same Industry, the average monthly price growth was 26%, and the average quarterly price growth was 26%. MMIRF experienced the highest price growth at 247%, while BRRGF experienced the biggest fall at -99%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -31%. For the same stocks of the Industry, the average monthly volume growth was -48% and the average quarterly volume growth was -15%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 62
SMR Rating: 94
Profit Risk Rating: 95
Seasonality Score: 26 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I. Advisor
published Earnings

RPHM is expected to report earnings to fall 2.02% to -55 cents per share on March 20

Reneo Pharmaceuticals RPHM Stock Earnings Reports
Q4'23
Est.
$-0.56
Q3'23
Est.
$-0.57
Q2'23
Missed
by $0.12
Q1'23
Est.
$-0.60
Q4'22
Beat
by $0.03
The last earnings report on November 13 showed earnings per share of -56 cents, meeting the estimate of -56 cents. With 345.07K shares outstanding, the current market capitalization sits at 196.54M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
18575 Jamboree Road
Phone
+1 858 283-0280
Employees
48
Web
https://www.reneopharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SGQIX35.96N/A
N/A
DWS International Growth Inst
SSFRX347.13N/A
N/A
State Street Equity 500 Index R
FGKMX84.12N/A
N/A
Fidelity Advisor® Communication Svcs Z
CAABX22.42N/A
N/A
ClearBridge Sustainability Leaders C
CGLAX15.43N/A
N/A
Calvert Global Equity Fund Class A

RPHM and

Correlation & Price change

A.I.dvisor tells us that RPHM and OMGA have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RPHM and OMGA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RPHM
1D Price
Change %
RPHM100%
+10.69%
OMGA - RPHM
29%
Poorly correlated
-3.12%
ALZN - RPHM
25%
Poorly correlated
-5.36%
FATE - RPHM
24%
Poorly correlated
-4.15%
GRTX - RPHM
24%
Poorly correlated
-3.17%
KURA - RPHM
23%
Poorly correlated
+2.51%
More